RESUMEN
BACKGROUND: Urogenital tumors are among the most common solid malignancies after kidney transplantation (TX). OBJECTIVE: We analyzed the incidence and mortality of urogenital tumors after kidney TX in our own patient population as well as answered the question of recommended follow-up necessity and frequency in this cohort. MATERIALS AND METHODS: Retrospective monocentric data collection of tumor diseases and the most common urogenital tumors after kidney TX at the Transplant Center Dresden between 2010 and 2020 was done. From this, we derived recommendations for a useful follow-up concept. RESULTS: A total of 13% (93/710) of kidney TX patients developed a neoplasm. Older patients (60.1⯱ 10.6 vs. 53.8⯱ 12.5; pâ¯< 0.001), with higher Charlson scores (≥â¯4: 68% vs. 46%; pâ¯< 0.001) and a previous tumor history (18% vs. 8%; pâ¯< 0.001) were more likely to develop a neoplasm after transplantation. In the multivariate analysis, previous tumor history was found to be an independent predictor of tumor development after renal transplantation (OR 2.2; 95%-KI [1.2-4.1]; pâ¯= 0.01). Urogenital tumors accounted for 30% (28/93) of all malignancies. Renal cell carcinoma of the native kidney was the most common (nâ¯= 12) neoplasm, followed by prostate cancer (nâ¯= 9). CONCLUSION: Most solid malignancies after kidney TX arise from the urinary tract. Due to their frequency, there is an urgent need for specialized urological therapy and long-term follow-up care. Even before listing for TX, risk factors can be recognized and individual concepts for follow-up care can be developed.
Asunto(s)
Carcinoma de Células Renales , Neoplasias Renales , Trasplante de Riñón , Neoplasias Urogenitales , Masculino , Humanos , Trasplante de Riñón/efectos adversos , Incidencia , Estudios Retrospectivos , Carcinoma de Células Renales/epidemiología , Neoplasias Urogenitales/epidemiología , Neoplasias Renales/epidemiologíaRESUMEN
Urological complications after kidney transplantation can cause a major reduction in renal function. Surgical complications like urinary leakage and ureteral obstruction need to be solved by a specialist in the field of endourological procedures and open surgical interventions. The article summarizes this and other common urological problems after kidney transplantation.
Asunto(s)
Trasplante de Riñón/efectos adversos , Obstrucción Ureteral/etiología , Obstrucción Ureteral/cirugía , Trastornos Urinarios/etiología , Trastornos Urinarios/cirugía , Medicina Basada en la Evidencia , Humanos , Resultado del Tratamiento , Procedimientos Quirúrgicos Urológicos/métodosRESUMEN
Antibodies directed against HLA antigens of a given donor represent the most prominent cause for hyper-acute and acute rejections. In order to select recipients without donor-specific antibodies the complement-dependent cytotoxicity (CDC-) crossmatch as the standard procedure was established. As a functional assay it strongly depends on the availability of isolated donor lymphocytes and in particular on their vitality. However, due to several diseases or pharmacological treatment of a given recipient unexpected "false-positive" results of the CDC-crossmatch may arise. We here present three groups of patients which demonstrate the limits of the conventional crossmatch. 1) Kidney recipients before living donations exhibited positive CDC-reactions due to their conditioning using the therapeutical anti-CD20 mAb Rituximab (n=7), routinely used to deplete B-cells, or the anti-CD25 mAb basiliximab (n=2) to inhibit the proliferation of activated T-cells. 2) Recipients suffering from various leukaemias (n=5) exhibited "positive" CDC-crossmatches using PBL of the donors, although formerly these patients had never shown anti-HLA antibodies. Instead of donor-specific allo-antibodies, cytostatic agents such as 6-mercaptopurine led to an unspecific cell death. 3) Patients projected for post mortem or living kidney donations (n=44) exhibited "positive" CDC-crossmatch results which were not in accordance with their former antibody status and, partially, with high degrees of HLA-matching. These implausible results were due to underlying auto-immune diseases, mainly of the systemic immune complex type III such as lupus erythematosus, mainly leading to false-positive B-cell crossmatches by immune complexes binding to Fcγ-receptors. In all these 58 cases the alternatively performed ELISA-based "Antibody Monitoring System" (AMS-) crossmatch assay was not artifically affected, suggesting that this assay may be comprehensively established at least for the cases described.
Asunto(s)
Proteínas del Sistema Complemento/inmunología , Pruebas Inmunológicas de Citotoxicidad , Antígenos HLA/inmunología , Prueba de Histocompatibilidad/métodos , Histocompatibilidad , Isoanticuerpos/sangre , Trasplante de Riñón , Enfermedades Autoinmunes/inmunología , Ensayo de Inmunoadsorción Enzimática , Reacciones Falso Positivas , Alemania , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Humanos , Trasplante de Riñón/inmunología , Leucemia/inmunología , Linfocitos/inmunología , Valor Predictivo de las Pruebas , Reproducibilidad de los Resultados , Acondicionamiento Pretrasplante/efectos adversos , Resultado del TratamientoRESUMEN
Fournier gangrene is a necrotizing fasciitis of the perineal and genital region, which almost exclusively affects men. The cause is a polymicrobial infection associated with superficial trauma, urological diseases and operations, as well as colorectal diseases. Diabetes mellitus, alcoholism, immunosuppression and other severe illnesses are frequent co-factors. Immediate administration of systemic broad-spectrum antibiotic therapy with coverage of both gram-positive and gram-negative bacteria combined with surgical debridement and intensive medical care can lower the high mortality rate of this condition.
Asunto(s)
Urgencias Médicas , Gangrena de Fournier/diagnóstico , Enfermedades de los Genitales Masculinos/diagnóstico , Enfermedades del Pene/diagnóstico , Escroto , Infecciones Estreptocócicas/diagnóstico , Streptococcus pyogenes , Adulto , Cefotaxima/uso terapéutico , Terapia Combinada , Quimioterapia Combinada , Estudios de Seguimiento , Gangrena de Fournier/patología , Gangrena de Fournier/cirugía , Enfermedades de los Genitales Masculinos/patología , Enfermedades de los Genitales Masculinos/cirugía , Humanos , Masculino , Metronidazol/uso terapéutico , Necrosis , Enfermedades del Pene/patología , Enfermedades del Pene/cirugía , Escroto/patología , Escroto/cirugía , Piel/patología , Infecciones Estreptocócicas/patología , Infecciones Estreptocócicas/cirugía , Tobramicina/uso terapéuticoRESUMEN
OBJECTIVES: To investigate the prevalence and distribution of comorbidity and its association with perioperative complications in patients undergoing radical prostatectomy (RPE). METHODS: In 431 unselected RPE patients, the American Society of Anesthesiologists Physical Status classification (ASA-PS), the New York Heart Association classification of cardiac insufficiency (NYHA), the classification of angina pectoris of the Canadian Cardiovascular Society (CCS), height, weight, the body mass index (BMI), and the number of concomitant diseases (NCD) were assessed and related to perioperative cardiovascular complications. RESULTS: In RPE patients less than 70 years old, comorbidity rose nearly continuously with increasing age. However, after reaching an age of 70 years, the proportion of NYHA-0 patients increased (60-64 years, 86%; 65-69 years, 85%; >or=70 years, 87%). Furthermore, the severe comorbidities decreased in patients selected for RPE aged 70 or more years. There was a nonsignificant trend towards higher comorbidity in patients with perioperative cardiovascular complications. CONCLUSIONS: These data suggest that documentation of the distribution of ASA-PS, CCS, NYHA and of concomitant diseases might be helpful to characterize the general health status and the degree of selection of prostate cancer treatment populations especially in series with a high portion of patients aged 70 or more years. Concerning perioperative complications, the individual predictive value of comorbidity seems to be poor in the radical prostatectomy setting.
Asunto(s)
Angina de Pecho/epidemiología , Prostatectomía/efectos adversos , Neoplasias de la Próstata/cirugía , Factores de Edad , Anciano , Enfermedades Cardiovasculares/epidemiología , Comorbilidad , Diabetes Mellitus/epidemiología , Humanos , Hipertensión/epidemiología , Complicaciones Intraoperatorias , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias , Prevalencia , Neoplasias de la Próstata/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Estudios Retrospectivos , Tromboembolia/epidemiologíaRESUMEN
BACKGROUND: Androgenic anabolic steroids have been suspected of activity as carcinogens in the development of carcinoma and angiosarcoma of the liver and adenocarcinoma of the prostate. Although the proliferation of smooth muscle cells is stimulated by sexual steroids, to the authors' knowledge a possible relation between androgenic anabolic steroids and the development of leiomyosarcoma has not previously been reported in humans. METHODS: A 32-year-old man underwent right radical orchiectomy for a tumor of the upper pole of the right testicle. Routine histopathologic examination and immunohistochemical staining were performed. RESULTS: The tumor was identified as an intratesticular leiomyosarcoma based on its typical growth pattern and the characteristic immunohistochemical staining profile. The patient reported a 5-year history of systematic use of high dose Oral-Turinabol (4-chloro-1-dehydro-17alpha-methylteststerone) that began at age 18 years and stopped approximately 9 years before presentation. CONCLUSIONS: The rarity of intratesticular leiomyosarcoma, the experimental induction of similar tumors in animals by androgens and estrogens, and the unusually young age at presentation of the patient in the current study support the hypothesis that high dose doping with androgenic anabolic steroids could have played a cocarcinogenic role in the development of the tumor in this case.
Asunto(s)
Doping en los Deportes , Leiomiosarcoma/patología , Neoplasias Testiculares/patología , Testosterona/análogos & derivados , Actinas/análisis , Adulto , Desmina/análisis , Relación Dosis-Respuesta a Droga , Humanos , Inmunohistoquímica , Leiomiosarcoma/inducido químicamente , Leiomiosarcoma/metabolismo , Masculino , Músculo Liso/metabolismo , Neoplasias Testiculares/inducido químicamente , Neoplasias Testiculares/metabolismo , Testosterona/efectos adversos , Vimentina/análisisRESUMEN
We report on a case of a splenunculus found in the renal fossa 14 years after left transperitoneal radical nephrectomy and splenectomy for renal cell carcinoma. The significance of splenunculi in differential diagnosis of space occupying lesions in the left renal bed is discussed.
Asunto(s)
Carcinoma de Células Renales/diagnóstico por imagen , Neoplasias Renales/diagnóstico por imagen , Recurrencia Local de Neoplasia/diagnóstico por imagen , Bazo/anomalías , Carcinoma de Células Renales/cirugía , Diagnóstico Diferencial , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Renales/cirugía , Persona de Mediana Edad , Factores de Tiempo , Tomografía Computarizada por Rayos XRESUMEN
Enhanced external counterpulsation (EECP) is a noninvasive treatment modality which can increase arterial blood flow in peripheral and coronary arterial disease. Several studies have demonstrated an increase in the flow of the internal iliacal artery and in carotid and renal perfusion during EECP treatment. We investigated the effect of EECP in patients with erectile dysfunction (ED). Thirteen patients were treated with EECP for 20 days, 1 h per day. Patients reported a significant improvement of penile rigidity after completion of the EECP treatment and a significant improvement of penile peak systolic flow was measured by Doppler sonography. No adverse effects were observed. In conclusion, EECP seems to be an effective treatment modality in patients with ED.
Asunto(s)
Contrapulsación/métodos , Factores de Crecimiento Endotelial/sangre , Disfunción Eréctil/terapia , Linfocinas/sangre , Adulto , Anciano , Disfunción Eréctil/diagnóstico , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Satisfacción del Paciente , Erección Peniana/fisiología , Resultado del Tratamiento , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
Herein we report our experience with a clinical trial of intracavernous injection of vasoactive substances (Papaverin, Dibenzyran, Regitin) in 41 patients suffering from erectile dysfunction for longer than 1 year. In 14 out of 33 patients the application of papaverin alone was already sufficient to produce an excellent erection (T/E-grade 4) under clinical conditions. The simultaneous injection of two agents (Papaverin + Dibenzyran or Papaverin + Regitin) in patients with no or insufficient response to papaverin improved the results additionally. Besides a positively effect of delay from the injection to the erection could be observed in comparison with an injection of only papaverin. In conclusion, this method combined with an autoinjection therapy is an alternative approach to treat certain patients with erectile dysfunction.